FWP - Forward Pharma A/S

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.34
+0.17 (+2.37%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.17
Open7.23
Bid6.86 x 1000
Ask7.69 x 1100
Day's Range6.85 - 7.34
52 Week Range5.26 - 11.01
Volume21,150
Avg. Volume45,286
Market Cap49.846M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 11, 2017
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares

    COPENHAGEN, Denmark, Nov. 26, 2019 -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the.

  • GlobeNewswire

    Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange

    Forward Pharma A/S (FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. This follows the development in the Company’s American Depositary Shares (“ADSs” or “shares”) price after the Settlement and License Agreement with Biogen, and the significant return of capital to its shareholders in 2017. On June 21, 2019, the Company received a written notice from the Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the requirement for continued listing on the Nasdaq Global Select Market to maintain a minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000, as set forth in Nasdaq Listing Rule 5450(b)(1)(C) (the “MVPHS Notice”).

  • GlobeNewswire

    Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2018

    Forward Pharma A/S (FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial results for the year ended December 31, 2018. During the year ended December 31, 2017, we recognized as revenue the $1.25 billion nonrecurring non-refundable fee (“Non-refundable Fee”) that was received during February 2017 in connection with the Settlement and License Agreement (“License Agreement”) entered into with two wholly owned subsidiaries of Biogen, Inc. (collectively, “Biogen”).

  • GlobeNewswire

    Forward Pharma to Participate in the DKBIO2019 Life Science Investor Conference

    Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the DKBIO2019 life science investor conference in New York, NY. Dr. Svendsen will present a corporate update on Thursday, April 11, 2019 at 1:00 PM ET and will be available for one-on-one meetings. Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.